pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Luxturna
drug · gene
save

voretigene neparvovec

Phase 2updated 6mo ago
by F. Hoffmann-La Roche Ltd🔗 ChEMBL
Phase 2
community read0 votes

Gene drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.

targets

Retinoid isomerohydrolase

all catalysts(0)

nothing on the calendar yet

Trials studying voretigene neparvovec

  • —A Patient Registry Study for Patients Treated With Voretigene Neparvovec in UScompletedn=87
  • phase2Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2active not recruitingn=12
  • phase3Study of Efficacy and Safety of Voretigene Neparvovec in Japanese Patients With Biallelic RPE65 Mutation-associated Retinal Dystrophyactive not recruitingn=4
  • phase3Safety and Efficacy Study in Subjects With Leber Congenital Amaurosisactive not recruitingn=31

News(3)

  • Emerging biotech hubs step up as innovation economics evolve
    How India and other emerging hubs for drug development can be key to reshaping medical costs globally.
    biospace · 9h ago
  • Update: FDA investigates Novartis' Zolgensma following 9 cases of tumors in treated patients
    After Novartis confirmed the reports of tumors in patients who have been treated with the spinal muscular atrophy gene therapy, the FDA will determine if any regulatory action is needed for Zolgens…
    biospace · 6d ago
  • Novartis confirms 9 reported cases of tumors in patients treated with Zolgensma
    Advocates are sounding the alarm on social media as they learn from their doctors that Novartis has received reports of tumors in patients who have been treated with the spinal muscular atrophy gen…
    biospace · 10d ago
brand
Luxturna
trade names
Luxturna
generic
voretigene neparvovec-rzyl
MOA
Retinoid isomerohydrolase exogenous gene
indication
Choroideremia
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 2h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?